Identifying biomarker-driven subphenotypes of cardiogenic shock: analysis of prospective cohorts and randomized controlled trials
Open Access
- 18 December 2024
- journal article
- research article
- Published by Elsevier in eClinicalMedicine
- Vol. 79, 103013
Abstract
No abstract availableKeywords
Funding Information
- Sydäntutkimussäätiö
- Aarne Koskelon Säätiö
- Seventh Framework Programme
- CIHR
This publication has 44 references indexed in Scilit:
- Management of cardiogenic shock: state-of-the-artIntensive Care Medicine, 2024
- Coronavirus disease 2019 subphenotypes and differential treatment response to convalescent plasma in critically ill adults: secondary analyses of a randomized clinical trialIntensive Care Medicine, 2022
- Validation of cardiogenic shock phenotypes in a mixed cardiac intensive care unit populationCatheterization and Cardiovascular Interventions, 2022
- Safety and tolerability of non-neutralizing adrenomedullin antibody adrecizumab (HAM8101) in septic shock patients: the AdrenOSS-2 phase 2a biomarker-guided trialIntensive Care Medicine, 2021
- Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association ( HFA ), European Society of Cardiology ( ESC )European Journal of Heart Failure, 2021
- Dipeptidyl peptidase 3, a marker of the antagonist pathway of the renin–angiotensin–aldosterone system in patients with heart failureEuropean Journal of Heart Failure, 2021
- Shock in the cardiac intensive care unit: Changes in epidemiology and prognosis over timeAmerican Heart Journal, 2021
- Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for SepsisJAMA, 2019
- Clinical Picture and Risk Prediction of Short-Term Mortality in Cardiogenic ShockEuropean Journal of Heart Failure, 2015
- Comparing two correlated C indices with right‐censored survival outcome: a one‐shot nonparametric approachStatistics in Medicine, 2014